Ingredient or product comparison
Comparison of GHK-Cu Safety Data Across Administration Routes
Topical Dermal 0.5–5% concentration 8 weeks – 18 months Mild erythema in <5% of subjects, self-resolving No measurable systemic absorption Gold-standard safety profile. Suitable for long-term daily use with no monitoring required Subcutaneous Injection 0.5–3 m
This source-based comparison does not add ratings or recommend a winner.
- Topical Dermal
- 0.5–5% concentration
- 8 weeks – 18 months
- Mild erythema in <5% of subjects, self-resolving
- No measurable systemic absorption
- Gold-standard safety profile. Suitable for long-term daily use with no monitoring required
- Subcutaneous Injection
- 0.5–3 mg/kg
- Single dose – 12 weeks
- Transient injection-site tenderness in 8–12% of subjects
- Transient elevation to 1.2× baseline, normalizing within 48 hours
- Excellent safety at therapeutic doses. Appropriate for clinical protocols with standard post-injection site monitoring
- Oral Administration
- 1–10 mg/kg daily
- 4 weeks – 6 months
- None documented at any dose
- No significant elevation due to low bioavailability (8–12%)
- Safe but inefficient. Poor absorption limits clinical utility rather than safety concerns